DES - transgenderism and birth defects

Washington Post
The Washington Post reports that "DES was the biggest nostrum in quackery since snake oil . . . the medical community looked the other way. They didn't want to admit the mistake they made."

The DES debacle demonstrates the harm caused by the medical community when it fails to abide by the precautionary principle--"First, do no harm." Prescribing drugs without definitive evidence of their safety is irresponsible. The DES case should serve as a lesson: it's adverse effects are long-lasting, indeed they affect the health of women who took the drug during pregnancy, their daughters, and, it turns out, they affect the health of their sons and grandchildren.

The daughters of mothers who took DES "suffered malformed reproductive organs, which would later lead to increased infertility, tubal pregnancies and miscarriage, effectively robbing many of the chance to bear their own children." Furthermore, "Exposure to the drug also harmed male children, who face an increased risk for epididymal cysts -- non-cancerous growths on the testicles -- and varicose veins on the testicles."

Today, public officials--including the FDA and NIMH--and the medical community are similarly complicit in their failure to protect children and fetuses from the hazards posed by mind altering drugs. SSRI antidepressants are being prescribed recklessly to pregnant women and millions of previously healthy children.

The DES case demonstrates the tragic consequences of prescribing drugs whose benefits are not proven, but whose early adverse effects can be detected, and whose future long-lasting adverse effects on the developing brain and nervous system can be foreseen. FDA's failure to protect children and unborn fetuses is irresponsible.

Center for Disease Control
Diethylstilbestrol (DES) is a drug once prescribed during pregnancy to prevent miscarriages or premature deliveries. In the U.S. an estimated 5 to 10 million persons were exposed to DES from 1938 to 1971, including pregnant women prescribed DES and their children. In 1971, the Food and Drug Administration (FDA) advised physicians to stop prescribing DES because it was linked to a rare vaginal cancer.

After more than 30 years of research, there are confirmed health risks associated with DES exposure. However, not all exposed individuals will experience DES-related health problems. Whether you know for sure or suspect you were exposed to DES, you can use CDC's DES Update to learn more about DES exposure and what you can do about it.


What is DES?

Diethylstilbestrol (DES) is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. First prescribed by physicians in 1938 for women who experienced miscarriages or premature deliveries, DES was originally considered effective and safe for both the pregnant woman and the developing baby.

In the United States, an estimated 5-10 million persons were exposed to DES during 1938-1971, including women who were prescribed DES while pregnant and the female and male children born of these pregnancies. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.

More than 30 years of research have confirmed that health risks are associated with DES exposure. However, not all exposed persons will experience DES-related health problems. CDC's DES Update has more information about the health risks associated with DES exposure.

Scientific Physical 
Proof Of Transsexualism
Transsexualism and sex changes through Chemistry Articles 

Pubertal blockade safe for pediatric patients with gender identity disorder

Pubertal blockade can safely be initiated in pediatric patients who experience gender identity disorder, according to researchers at the Canadian Pediatric Endocrine Group 2012 Meeting. With exposure to hormones such as estrogen or testosterone later in their adolescence, these patients will experience normal metabolic processes.
“If kids are persisting at puberty [about the need to be the other gender], they will almost always persist,” said Daniel Metzger, MD, FRCPC, a pediatric endocrinologist at BC Children’s Hospital in Vancouver, British Columbia, Canada, and a clinical professor, division of endocrinology in the department of pediatrics, University of British Columbia in Vancouver.
Metzger spoke about the endocrine management of transgender youth and said pediatric patients who experience gender identity disorder require watchful management to reduce the risks for suicidality, depression, drug use and eating disorders, which are often secondary to gender identity disorder.
“These issues are frequently dealt with if patients can get on the road to transition,” Metzger said, noting that parental support is key in making the transition smooth.
Patients will undergo counseling and therapy if they express a desire to transition from male to female or female to male to ensure they are serious about their desire, he said.
“The effect of the puberty-blocking drugs is reversible,” Metzger said. “If they change their mind, they would come off the (puberty-blocking) drugs and enter puberty.”

American Psychiatric Association Calls for Improved Access to Transition Related Care

Even though transition-related medical procedures are medically necessary for many transgender and gender variant patients, they are often denied the care they need simply because of who they are. Today the American Psychiatric Association (APA) is calling for the elimination of barriers to access for transgender people.
According to the APA, the relentless discrimination transgender people face in virtually every aspect of life – from the workplace to adoption rights to public accommodations – makes it all the more important to ensure transgender individuals have access to high quality health care. In doing so, the APA joins other leading organizations like the American Medical Association and the American Psychological Association in pushing back against the harmful rhetoric that can too often drive discrimination.
The move also reflects the growing momentum within both the business and medical communities to provide more affordable, higher-quality access to care. For example, HRC’s Corporate Equality Index now rates companies on whether or not their health insurance options cover transition-related care. The business community has responded: in the very first year this criterion was added, the number of companies offering fully inclusive health benefits jumped from 85 to 206, a 144 percent increase.
HRC’s Healthcare Equality Index highlights this need for access to culturally competent healthcare for transgender people as well. The HEI helps medical facilities ensure they have the knowledge, skills, and resources to care well for their LGBT patients and their families. It also offers patients access to important resources, like finding a LGBT-friendly healthcare provider or having conversations about gender identity or sexual orientation with a doctor.
Learn more from the APA on both access to care for transgender patients, and the discrimination they too often face.